- Home
- PRQR vs RCS Comparison
PRQR vs RCS Comparison
Compare PRQR & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- RCS
- Stock Information
- Founded
- PRQR 2012
- RCS 1994
- Country
- PRQR Netherlands
- RCS United States
- Employees
- PRQR N/A
- RCS N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- PRQR Health Care
- RCS Finance
- Exchange
- PRQR Nasdaq
- RCS Nasdaq
- Market Cap
- PRQR 309.5M
- RCS 292.8M
- IPO Year
- PRQR 2014
- RCS N/A
- Fundamental
- Price
- PRQR $1.19
- RCS $5.77
- Analyst Decision
- PRQR Strong Buy
- RCS
- Analyst Count
- PRQR 6
- RCS 0
- Target Price
- PRQR $8.50
- RCS N/A
- AVG Volume (30 Days)
- PRQR 694.9K
- RCS 141.1K
- Earning Date
- PRQR 03-13-2025
- RCS 01-01-0001
- Dividend Yield
- PRQR N/A
- RCS 10.12%
- EPS Growth
- PRQR N/A
- RCS N/A
- EPS
- PRQR N/A
- RCS N/A
- Revenue
- PRQR $20,235,014.00
- RCS N/A
- Revenue This Year
- PRQR $39.44
- RCS N/A
- Revenue Next Year
- PRQR N/A
- RCS N/A
- P/E Ratio
- PRQR N/A
- RCS N/A
- Revenue Growth
- PRQR 196.41
- RCS N/A
- 52 Week Low
- PRQR $1.25
- RCS $4.51
- 52 Week High
- PRQR $4.62
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- PRQR 20.57
- RCS 34.00
- Support Level
- PRQR $1.25
- RCS $6.16
- Resistance Level
- PRQR $1.39
- RCS $6.30
- Average True Range (ATR)
- PRQR 0.09
- RCS 0.08
- MACD
- PRQR -0.02
- RCS -0.01
- Stochastic Oscillator
- PRQR 0.00
- RCS 10.94
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.